Skip to Content

Ferriprox (deferiprone) Disease Interactions

There are 2 disease interactions with Ferriprox (deferiprone):


Deferiprone (Includes Ferriprox) ↔ agranulocytosis/neutropenia

Severe Potential Hazard, Moderate plausibility. Applies to: Neutropenia, Infection - Bacterial/Fungal/Protozoal/Viral

Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.


Deferiprone (Includes Ferriprox) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

A clinical study to evaluate the effect of impaired hepatic function on the pharmacokinetics of deferiprone showed that mild and moderate hepatic impairment do not influence the pharmacokinetics of deferiprone and major metabolite, deferiprone 3-O-glucuronide. Based on the results, no dose adjustment is required in patients with mildly or moderately hepatic impairment. Caution is recommended when using this agent in patients with severe hepatic impairment as the pharmacokinetics of deferiprone and deferiprone have not been evaluated. It is recommended to monitor serum transaminase values monthly during therapy and to consider interruption if there is a persistent increase in serum transaminase levels. Close monitoring is recommended.

Ferriprox (deferiprone) drug interactions

There are 307 drug interactions with Ferriprox (deferiprone)

Ferriprox (deferiprone) alcohol/food interactions

There is 1 alcohol/food interaction with Ferriprox (deferiprone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.